Ambrisentan, a selective ERA, and bosentan, a dual blocker, are both available for therapy. We hypothesized that there are differences in the potential of ERAs to ameliorate inflammatory processes in human airway smooth muscle cells (HASMCs) and aimed to unravel underlying mechanisms. We used HASMC culture, ELISA and qRT-PCR. TNFα induced transcription and expression of CXCL2, CXCL3, GM-CSF and MMP12 in HASMCs. In concentration-response experiments, bosentan led to a significantly greater reduction of GM-CSF and MMP12 protein release than ambrisentan while there was no significant difference in their effect on GM-CSF and MMP12
ET-1 is produced as preproendothelin, released in its precursor form, big-ET-1, from the synthesizing cells and is subsequently cleaved by endothelin converting enzyme into the active 21 amino acid peptide. Discovered as a vasoconstrictor (Yanagisawa et al., 1988) , it is now known to also have an important role in inflammatory processes. Together with TNFα, ET-1 was described as a cytokine initiating inflammatory processes in the airways (Hamilton and Anderson, 2004) . It acts mainly locally and signals through ET A / B R subtypes (Benigni and Remuzzi, 1999) which have been
shown to be present on HASMCs (Flynn et al., 1998) .
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ERA were researched extensively after the discovery of ET-1 and were soon discovered to hold anti-inflammatory potential (Finsnes et al., 1997) . However, many setbacks occurred during these efforts: Tezosentan proved non-beneficial in acute and chronic heart failure (Kawanabe and Nauli, 2011; McMurray et al., 2007) , and despite encouraging results from previous clinical trials, bosentan did not show clinical efficacy in patients with histologically proven idiopathic pulmonary fibrosis in the BUILD-3 trial (King et al., 2011) . Nonetheless, clinical efficacy was shown for the treatment of patients with pulmonary arterial hypertension (PAH) and scleroderma-related digital ulcers, and recent results and flaws in previous trials justify research in abandoned areas (Kohan et al., 2012) .
Bosentan is an endothelin receptor antagonist with almost equal affinity to both ET A R (K i 4.75 ± 1.44 nM) and ET B R (K i 40.9 ± 12.3 nM; each in human muscle cells; Yuyama et al., 2004) and is, therefore, called a dual blocker (Clozel et al., 1994) . A trial in 7 female patients published in 2000 first showed a positive influence on pulmonary hypertension (PH) (Williamson et al., 2000) . It was subsequently approved for therapy in the European Union in 2002 as an orphan drug after two further clinical trials demonstrated efficacy in PH (Channick et al., 2001; Rubin et al., 2002) . Its efficacy in the treatment of PAH was first shown in a trial with 64 patients (Galié et al., 2005) . However, there is no clinical evidence to support an advantage of selective over dual ERA (Opitz et al., 2008) .
TNFα is an important cytokine in inflammatory airway diseases. It is implied in inflammatory and remodeling processes in chronic bronchitis, chronic obstructive pulmonary disease (COPD) and asthma, and leads to ASMC hyperplasia, bronchial vasoconstriction and emphysema-and pulmonary fibrosis-like changes in animal models (Mukhopadhyay et al., 2006) . Of note, anti-TNFα therapy proved nonbeneficial in COPD and raised concerns about the possible induction of malignancies (Rennard et al., 2007; Bongartz et al., 2006) .
GM-CSF is involved in inflammatory reactions throughout the body (Hamilton and
Anderson, 2004) with raised mRNA levels in bronchial bioptic tissue of atopic asthmatics (Bentley et al., 1993) , pulmonary inflammatory processes and lung fibrosis (Gajewska et al., 2003) . Its expression is induced by TNFα and prevents eosinophil apoptosis in asthma leading to an increased expression of inflammatory mediators (Esnault and Malter, 2001 ). GM-CSF levels are raised in induced sputum of COPD patients (Vlahos et al., 2006) . Its mRNA is rapidly degraded due to an adenosineuridine-rich sequence in its 3' untranslated region (Shaw and Kamen, 1986) but is stabilized by receptor signaling (Tebo et al., 2003) .
There is strong evidence for an involvement of matrix metalloproteinase 12 (MMP12) in airway inflammation and remodelling. Genetic polymorphisms of MMP12 have been associated with the development of COPD and decline in lung function (Mukhopadhyay et al., 2010; Joos et al., 2002) .
The chemokine (C-X-C motif) ligands 2 (CXCL2) and 3 (CXCL3) are activated in bronchoalveolar lavage cells of asthmatics resistant to corticosteroids (Goleva et al., 2008) and induce an increased migration of HASMCs from asthmatic patients suggesting a contribution to airway remodelling (Al-Alwan et al., 2013 ).
An increased expression of Interleukin-32 (IL-32) has been shown in macrophages, alveolar walls and bronchiolar epithelium of patients with COPD (Calabrese et al., This article has not been copyedited and formatted. The final version may differ from this version.
). Moreover, IL-32 levels are increased in the serum of asthmatic patients (Meyer et al., 2012) .
The aim of this study was to assess whether differences between selective versus dual ERA exist in their potential to ameliorate inflammatory processes in HASMCs, specifically the expression of GM-CSF, MMP12, CXCL2, CXCL3 and IL-32 in response to TNFα, and to achieve mechanistic insight into the associated pathways. To this end, we compared mRNA and protein expression in response to TNFα stimulation after blocking endothelin receptors with bosentan or ambrisentan in HASMCs.
Materials and Methods

Acquisition, isolation and cultivation of HASMCs
HASMCs were dissected from resected lung tissue of patients undergoing surgery for pulmonary tumors as previously established (Oltmanns et al., 2003) . Cultivation and characterisation was carried out as stated elsewhere (Raidl et al., 2007) . This study was approved by the ethics committees of the Universities of Cologne (02-004) and Bochum (4257-12), Germany, and all patients gave written informed consent.
Stimulation of HASMCs
Cells were cultivated until they reached subconfluence and then deprived of serum for 24 hours before stimulation as described elsewhere (Raidl et al., 2007) 
Quantitative reverse transcription-PCR (RT-PCR)
Quantitative RT-PCR was performed on DNA-free total RNA extracted from HASMCs as described previously (Knobloch et al., 2009; Knobloch et al., 2013) .
Statistical analysis
Statistical analyses were performed to examine the effects of TNFα or ET-1 alone or in combination with bosentan, ambrisentan, BQ123, BQ788, SB203580, PD098050
and/or actinomycin D on cytokine release or gene expression from HASMCs. Datasets were tested and confirmed for a Gaussian distribution by histogramm analysis.
The results are indicated as mean ± SEM (gaussian distribution) or as median with 25th to 75th interquatile range ± minimum/maximum (non-Gaussian distribution). (Knobloch et al., 2010; Knobloch et al., 2013) . Using these conditions, GM-CSF protein baseline release was 22.4 ± 5.1 pg/ml (mean ± SEM) and TNFα clearly induced GM-CSF release (Fig. 1A) . To investigate the effects of bosentan and ambrisentan in TNFα induces GM-CSF mRNA levels in HASMCs at two maximums: one after two hours of stimulation, which is insensitive to bosentan, and a second one after eight hours, which is sensitive to bosentan (Knobloch et al., 2009 ). Both bosentan and ambrisentan significantly reduced TNFα induced GM-CSF transcription after 8 hours of stimulation -notably, without significant differences ( Fig. 1C, D ; Tab. 1).
To check if this discrepancy between mRNA and protein sensitivity to bosentan and ambrisentan is specific for GM-CSF we tested four further cytokines: CXCL2, CXCL3, IL-32 and MMP12. Previously, mRNA upregulation by TNFα in HASMCs was shown for all of these cytokines by whole genome microarrays and qRT-PCR (Knobloch et al., 2013) . TNFα induced the release of CXCL2, CXCL3 and MMP12
but not of IL-32 protein from HASMCs ( Fig. 1E, H ; data not shown). TNFα-induced CXCL2 release was insensitive to bosentan and ambrisentan (data not shown).
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Therefore, IL-32 and CXCL2 were not considered for further analyses. Both ERAs did not modulate baseline MMP12 and CXCL3 levels (data not shown). Bosentan clearly reduced MMP12 protein release in TNFα-exposed cells; however, ambrisentan had no effect, though there was a trend for the highest concentration ( Fig. 1F ; Tab. 1).
The difference in the effects between the two ERAs was statistically significant. Both drugs reached maximal effects on GM-CSF mRNA at 1 µM ( Fig. 1D ) which is why we used this concentration for the analyses of ERA effects on further cytokine mRNA levels. Both ERAs did not modulate TNFα-induced MMP12 mRNA levels ( Fig. 1G ).
Both bosentan and ambrisentan partially reduced CXCL3 protein release and mRNA levels in TNFα-exposed cells but in both cases without differences between the two ERAs ( Fig 
Blocking ET A R with either BQ123 or ambrisentan led to a significant reduction of TNFα induced GM-CSF release. The additional blockade of ERK-1/-2 activity with PD098059 led to a further significant reduction in GM-CSF release; this was also significantly different in comparison to blocking ERK-1/-2 alone ( Fig. 2A) . When blocking ET B R with BQ788 there was also a significant reduction in TNFα induced GM-CSF release, but the additional blockade of ERK-1/-2 activity with PD098059 led to no further significant reduction in GM-CSF levels ( Fig. 2A) (Fig. 3) . ET-1 induced an increase in p38 MAPK phosphorylation, which was reduced by both ERA (Fig. 3) . Importantly, bosentan but not ambrisentan completely abolished p38 MAPK activity, and the differences in the effects between the two ERA were statistically significant (Fig. 3) . Summarized, these data show that both endothelin receptor subtypes signal through p38 MAPK but only ET B R also signals through ERK-1/-2 in HASMCs. 
anymore; however, the combined treatment showed a reduction (Fig. 2B) . ERAs reduced TNFα-induced GM-CSF release only partially and from the data obtained so far it could not be ruled out that endothelin receptor-independent GM-CSF expression in response to TNFα is mediated by ERK-1/-2, which could also explain the additive effects of ERK-1/-2 and p38 MAPK inhibition on GM-CSF shown in Fig. 2B . However, the combined treatment with PD098059 and bosentan did not show additional effects on GM-CSF compared to single treatments (Fig. 2C ) demonstrating that endothelinindependent GM-CSF regulation by TNFα does not require ERK-1/-2 activity.
ET B R protects GM-CSF but not MMP12 mRNA from degradation
TNFα led to a strong induction of GM-CSF transcription after 10 hours of stimulation (Fig. 4A ). To elucidate post-transcriptional effects of the endothelin receptor subtypes, we added actinomycin D after 8 hours of stimulation with TNFα to stop transcription. Then, we added bosentan or ambrisentan and measured GM-CSF mRNA.
Actinomycin D alone did not significantly reduce GM-CSF mRNA in TNFα-exposed HASMCs (Fig. 4A ). In the presence of actinomycin D both drugs significantly reduced GM-CSF mRNA compared to stimulation with TNFα alone (Fig. 4A ) indicating constitutive mRNA turnover. Importantly, in the presence of actinomycin D, bosentan but not ambrisentan reduced GM-CSF mRNA compared to incubation with actinomycin D alone (Fig. 4A) .
We conclude that ET B R protects GM-CSF mRNA from degradation. TNFα also induced MMP12 and CXCL3 mRNA after ten hours (Fig. 4B, C) . Actinomyin D reduced MMP12 mRNA but there was no additional effect when it was combined with bosentan or ambrisentan (Fig.4B ). CXCL3 mRNA levels were not modulated by Actinomycin D alone or in combination with ERAs (Fig. 4C ). This indicates that ET B R does not regulate MMP12 and CXCL3 mRNA stability.
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 5) . However, in the presence of bosentan or BQ788, a specific inhibitor for ET B R, TNFα did not significantly increase GM-CSF mRNA levels. These data confirm our conclusion stated above.
This article has not been copyedited and formatted. The final version may differ from this version. firmed by right heart catheterization were enrolled and randomized to receive either standard care or standard care plus bosentan for a period of 18 months. The average FEV 1 at baseline was 39% in the standard care group and 37% in the bosentan group. The authors reported a significant decrease in PAP, pulmonary vascular resistance and BODE index as well as a significant increase in the 6-min walking distance for the bosentan group. However, the trial was not double blinded and it seems no primary endpoint had been defined (Valerio et al., 2009 ).
While these results are interesting they concern patients suffering from advanced stages of COPD and PH. In these patients extensive lung remodeling with loss of functional tissue will have already taken place. It is important to stress, though, that the possible utility of ERA that results from our data lies in their potential to ameliorate inflammation and remodeling in early rather than late stages of chronic inflam- 
using a paired t-test and a one-sample t-test to a hypothetical value of 0 (= no reduction): * P < 0.05, ** P < 0.01, *** P < 0.001. 
